Gilead Sciences continues its divergence out of its original infectious disease beginnings and into cancer and now, more ...

Biotech giant Gilead Sciences, Inc. GILD has put up a strong performance amid a volatile market. Shares of this biotech giant ...

Galapagos NV. announced its plans to split into two listed entities by mid-2025 by spinning off its activities focused on ...

Gilead’s investment will let it assess the therapeutic potential of targeting STAT6, a transcription factor involved in IL-4 ...

The beleaguered Belgian firm Galapagos is splitting itself into two companies, with the brandname biotech prioritizing ...

South San Francisco biotech Pionyr was sold two years ago. Now three of its leaders want to test a trio of drugs beyond ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

By mid-2025, the biotech will split into two entities: a new, as-yet-unnamed innovative medicines specialist and a cell ...

Kite Pharma is flying high with the addition of a new member to its senior leadership team. | Kite Pharma is flying high with ...

Alongside plans to spin out a new company, the Belgian drugmaker said it will cut some 300 positions, or about 40% of its ...

Shoreline Biosciences, a gene editing and cell therapy biotech, has let go of staffers dedicated to a cell therapy project ...

The biotech industry is booming thanks to the rising demand for personalized medicine, investment in innovations, and ongoing ...